

Ophthalmological Complications in Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis

Sauman Singh-Phulgenda^{1,2}, Prabin Dahal^{1,2}, Rishikesh Kumar³, Abdalla Munir^{1,2,4}, Caitlin Naylor^{1,2}, Manju Rahi⁵, Eli Harriss⁶, Niyamat Ali Siddiqui³, Fabiana Alves⁷, Ahmed Musa⁴, Kasia Stepniewska^{1,2}, Shyam Sundar⁸, Philippe J Guerin^{1,2}, Krishna Pandey³

¹Infectious Diseases Data Observatory (IDDO), Oxford, UK, ²Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, ³ICMR-Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Patna, India, ⁴Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan, ⁵Indian Council of Medical Research (ICMR), New Delhi, India, ⁶The Knowledge Centre, Bodleian Health Care Libraries, University of Oxford, Oxford, OX3 7DQ, UK, ⁷Drugs for Neglected Diseases initiative, Geneva, Switzerland, ⁸Infectious Disease Research Laboratory, Department of Medicine, Institute of Medical, Sciences, Banaras Hindu University, Varanasi, India



Objective

- A systematic literature review was conducted to describe the occurrence of ophthalmological conditions and/or adverse events in patients treated for VL and PKDL

Methodology

- Systematic review** of Ovid Embase, Ovid MEDLINE, Web of Science, Embase, Medline, Scopus, and WHO global Index Medicus published between 1stJan 1974 and 30th Jan 2023
- Patient:** Any patient with a diagnosis of VL or PKDL regardless of age and gender
- Intervention:** Any antileishmanial drug used for the treatment of VL/PKDL
- Comparator:** Not restricted by comparator
- Outcomes:** One or more ocular occurrences

Contact

info@iddo.org
@IDDOnews
iddo.org



ICMR RMRIMS
INDIAN COUNCIL OF MEDICAL RESEARCH
RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES

Results

- A total of 1821 records were identified of which 1683 were excluded at title/abstract screening and 85 excluded at full-text stage leading to 53 unique records included (1924-2022; **Figure 1**)
- From 37 records in VL, 120 ocular events were reported of which 32 occurred at baseline (**Figure 2**), 61 (**Figure 3**) following a treatment and the time of occurrence was unclear in 27
- From 17 records in PKDL, 38 complications were reported of which 1 occurred at baseline (conjunctival involvement), 33 occurred after a treatment (**Figure 4**), and time was unclear in 4
- The following reports had unclear time: conjunctivitis (n=1), blindness (n=1), uveitis (n=2)




Figure 1. PRISMA flow chart




Figure 2. Ocular events at baseline in VL




Figure 3. Ocular events reported following a treatment in VL




Figure 4. Ocular events reported after treatment in PKDL